3 Lessons From An Alarming Case Of Mistaken Cancer Gene Test Results And Surgery
By Elaine Schattner,
Forbes
| 10. 29. 2017
A horrifying story broke last week about a 36-year-old Oregon woman who had elective surgery to remove her uterus and breasts. Elisha Cooke-Moore underwent a prophylactic total hysterectomy and bilateral mastectomy, with nipple-sparing reconstruction and implants, after medical practitioners informed her she had cancer-causing genes. Only later, she learned she didn’t have the abnormality about which she’d been informed. There’s a lawsuit.
As reported in The Washington Post, Cooke-Moore expressed concerns to a doctor about her family’s cancer history before getting tested for mutations in BRCA-1, BRCA-2 and related genes in 2015. A nurse practitioner reviewed the results and erroneously told her she had Lynch syndrome because of an MLH1 mutation. BRCA testing was “negative.” It’s not clear if any doctor directly reviewed the lab report. An obstetrician-gynecologist informed Cooke-Moore that her chances of developing breast cancer were 50% and for uterine cancer up to 80%. In 2016, at least two surgeons operated.
Cooke-Moore discovered the mistake while looking over her medical records: The MLH1 result was “negative,” she noted in 2017. “I am damaged for the rest of my...
Related Articles
By Emily Baumgaertner Nunn, The New York Times | 06.11.2026
When scientists at Columbia University announced they had used a newer technology to precisely edit the genes of human embryos last week, they set the academic community ablaze with debate. Is this good news or bad? How fast will...
By Gina Kolata, The New York Times | 06.11.2026
On my second visit with Nancy Wexler at her Manhattan apartment, she had a gift for me. It was a copy of her newly published memoir, “My Life, My Science: Pursuing a Cure for Huntington’s Disease.”
It had been signed...
By Samuelle Fajutrao Falk , The Conversation | 06.26.2026
When my colleagues and I asked autistic people and parents of autistic children in Sweden how they feel about genetic research in autism, one response stood out: “I hope genetic research finds new ways to help us, not erase us.”...
By Rebecca Simkin, BioNews | 06.29.2026
The US Food and Drug Administration (FDA) is allowing biotech company Regenxbio to reapply for licensing of a gene therapy for Hunter syndrome, in a reversal of its previous decision. Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a...